Daniel Douglas von Hoff

Daniel Douglas Von Hoff founded Medelis, Inc. in 2003, Cylene Pharmaceuticals, Inc. in 1997, where he is working as Director & Vice President-Medical Affairs from 2010, and Systems Oncology LLC in 2015, where he is working as Director & Chief Clinical Strategist from 2015.
Dr. Von Hoff also founded ILEX Oncology, Inc. and Investigational New Drugs.
Dr. Von Hoff also currently works at Caris Molecular Profiling Institute, Inc., as Executive Director-Tissue Banking & Analysis, the University of Arizona, as Professor, HonorHealth Ambulatory, as Physician, Translational Genomics Research Institute, as Professor, Texas University of Health Center at San Antonio, as Professor, and TVP Management Co. LLC, as Principal.
Dr. Von Hoff also formerly worked at Genta, Inc., as Independent Director from 2011 to 2012, INSYS Therapeutics, Inc., as Director-Scientific Development, Cancer Therapy & Research Center Foundation, as Director-Drug Development, Aptose Biosciences, Inc., as Senior Vice President-Medical Affairs, US Oncology, Inc., as Chief Scientific Officer, The University of Texas at Austin, as Professor, the University of California, Berkeley, as Principal, The Mayo Clinic (Old), as Professor, Mayo Foundation for Medical Education & Research, as Professor, American Society of Clinical Oncology, Inc., as Member, and American Association for Cancer Research, as President.
Dr. Von Hoff received his doctorate degree from The Trustees of Columbia University in The City of New York, undergraduate degree from Carroll College (Montana), and undergraduate degree from Columbia University College of Physicians & Surgeons.